Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes
NCT04696159 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2025-07-24
Summary
This study will assess changes in glycemic control in 40 patients with diabetes who undergo per-oral pyloromyotomy (POP) for medically refractory gastroparesis.
Conditions
- Diabetes Mellitus
- Gastroparesis With Diabetes Mellitus
- Gastroparesis
Interventions
- PROCEDURE
-
Pyloromyotomy
Endoscopic Per-Oral Pyloromyotomy (POP)
Sponsors & Collaborators
-
Society of American Gastrointestinal and Endoscopic Surgeons
collaborator OTHER -
Matthew Allemang
lead OTHER
Principal Investigators
-
Mathew Allemang, MD · The Cleveland Clinic
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-01-04
- Primary Completion
- 2026-06-30
- Completion
- 2027-06-30
Countries
- United States
Study Locations
More Related Trials
-
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
NCT00861809 ·Status: COMPLETED ·Phase: PHASE2
-
A Scintigraphy Study in Adults With Diabetic Gastroparesis
NCT04208698 ·Status: TERMINATED ·Phase: PHASE2
-
Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options
NCT02365740 ·Status: UNKNOWN ·Phase: NA
-
Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176760 ·Status: UNKNOWN ·Phase: NA
-
Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
NCT00489645 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus
NCT00889486 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of GLP-1 Agonists on Gastric Volume
NCT05854979 ·Status: COMPLETED
-
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
NCT01176890 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Gastric Emptying on Blood Glucose Profile of Type 1 Diabetes Mellitus and Its Therapeutic Strategies
NCT06173934 ·Status: RECRUITING ·Phase: NA
-
Trial Investigating Efficacy of G-POEM
NCT05830994 ·Status: UNKNOWN ·Phase: NA
-
Vagal Nerve Stimulation and Glucose Metabolism
NCT01117311 ·Status: COMPLETED ·Phase: NA
-
The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes
NCT05284344 ·Status: COMPLETED
-
GLP-1 Signaling in Truncally Vagotomized Subjects
NCT02940184 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
NCT01557296 ·Status: COMPLETED ·Phase: PHASE2
-
Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients
NCT00596973 ·Status: WITHDRAWN ·Phase: PHASE4
-
An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus
NCT01286090 ·Status: TERMINATED ·Phase: PHASE4
-
Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response
NCT01534442 ·Status: UNKNOWN ·Phase: NA
-
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
NCT03281577 ·Status: COMPLETED ·Phase: PHASE2
-
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
NCT00537719 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
NCT02289846 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
NCT00809705 ·Status: COMPLETED ·Phase: PHASE3
-
Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass
NCT05057819 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
NCT00390975 ·Status: TERMINATED ·Phase: PHASE4
-
Oral Glucose Stimulation in Normal-weight and Obese Volunteers
NCT01875575 ·Status: COMPLETED ·Phase: NA
-
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
NCT01452815 ·Status: COMPLETED ·Phase: PHASE2